Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis
Status:
Completed
Trial end date:
2021-03-24
Target enrollment:
Participant gender:
Summary
Infected pancreatic necrosis and its related septic complications are the major cause of
death in patients with acute pancreatitis, therefore prevention of pancreatic infection is of
great clinical value in the treatment of AP.
Immunosuppression and disorders characterized by decreased HLA-DR expression and unbalanced
CD3/CD4+/CD8+ T cells of PBMC are thought to be associated with the development of pancreatic
infection. Thymosin alpha 1 has been shown to have immunomodulatory properties and its
effects in preventing pancreatic infection was not well studied. To evaluate the effects of
TA1 use in the early phase on preventing pancreatic infection, immunomodulation and clinical
outcomes in patients with AP,we aimed to design this study.
Phase:
Phase 4
Details
Lead Sponsor:
Weiqin Li
Collaborators:
Clinical Medical College of Yangzhou University Jiangsu Province Hospital of Traditional Chinese Medicine Luoyang Central Hospital Qilu Hospital of Shandong University Second Affiliated Hospital of Nantong University the 908th Hospital of Chinese People's Liberation Army Joint Logistic Support Force The Affiliated Hospital of Henan University of Science and Technology The Affiliated Hospital of Qingdao University the Affiliated Nanhua Hospital, University of South China The First Affiliated Hospital of Anhui Medical University The First Affiliated Hospital of Nanchang University The First People's Hospital of Shangqiu Yijishan Hospital of Wannan Medical College Zhejiang Provincial People's Hospital Zunyi Medical College